Filters: Keyword is Dose-Response Relationship, Drug [Clear All Filters]
"Treatment of heroin dependence with buprenorphine in primary care." The American journal of drug and alcohol abuse 28, no. 2 (2002): 231-41. Abstract
"Under the counter: the diffusion of narcotic analgesics to the inner city street." Journal of ethnicity in substance abuse 4, no. 2 (2005): 97-114. Abstract
"Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S224-34. Abstract
"Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S235-46. Abstract
"Opioid dependence: rationale for and efficacy of existing and new treatments." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S173-7. Abstract
"The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S178-83. Abstract
"A trial of integrated buprenorphine/naloxone and HIV clinical care." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S184-90. Abstract
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?" The Lancet infectious diseases 10, no. 2 (2010): 133-7. Abstract
"DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions." Archives of internal medicine 170, no. 1 (2010): 109-10.
"Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers." The Journal of infectious diseases 202, no. 5 (2010): 745-51. Abstract
"Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S62-7. Abstract
"Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET." Journal of hepatology 62, no. 2 (2015): 286-93. Abstract
